trending Market Intelligence /marketintelligence/en/news-insights/trending/xdojehchnbff0pahyvg6va2 content esgSubNav
In This List

Pieris Pharmaceuticals closes common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pieris Pharmaceuticals closes common stock offering

Pieris Pharmaceuticals Inc. closed its underwritten public offering of 6,325,000 common shares at $8 apiece with gross proceeds of about $50.6 million.

The shares sold include the full exercise of the underwriters' option to buy up to an additional 825,000 common shares.

The Boston-based drugmaker plans to use the proceeds for working capital and general corporate purposes, including advancing the development of its drug candidates.

Jefferies, Cowen and Evercore ISI acted as joint book-running managers for the offering.